STOCK TITAN

Verona Pharma plc - VRNA STOCK NEWS

Welcome to our dedicated page for Verona Pharma plc news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma plc stock.

Verona Pharma plc (VRNA) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases that have significant unmet medical needs. Headquartered in both the United States and the United Kingdom, Verona Pharma is publicly traded on the NASDAQ Global Market and the London Stock Exchange.

The company's flagship product, Ensifentrine, is currently in development for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Ensifentrine is a dual inhibitor that has demonstrated potential in reducing inflammation and relaxing airway muscles, addressing critical gaps in the treatment of these chronic diseases. In addition to COPD and CF, Verona Pharma aims to expand its therapeutic pipeline to include treatments for other respiratory conditions such as asthma.

Verona Pharma's success is underpinned by a team of seasoned experts with extensive backgrounds in the discovery, development, and commercialization of respiratory therapies. The company has also forged strong partnerships with leading research institutions and advocacy organizations in the respiratory health sector. These collaborations have been instrumental in advancing their clinical programs and have garnered Verona Pharma several awards for innovation.

Recent achievements include the successful completion of Phase 2 clinical trials for Ensifentrine, which showed promising results in improving lung function and reducing symptoms in COPD patients. The company is now steering towards Phase 3 trials, marking a significant milestone in its mission to bring effective treatments to market.

Financially, Verona Pharma has demonstrated stability and growth, strengthening its financial flexibility through strategic funding rounds. This robust financial health supports ongoing research and development activities, ensuring sustained progress in their clinical programs. The company’s near-term goals include advancing Ensifentrine into late-stage clinical trials and exploring potential marketing authorizations.

For the latest updates on Verona Pharma’s research, financial performance, and upcoming milestones, stay tuned to the latest news and press releases.

Rhea-AI Summary
Verona Pharma plc (Nasdaq: VRNA) strengthens financial flexibility with a $400 million debt financing facility provided by Oxford Finance LLC and Hercules Capital, Inc. The facility will support the planned commercial launch of ensifentrine, Verona Pharma’s first-in-class product candidate, under review by the US Food and Drug Administration for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
none
-
Rhea-AI Summary
Verona Pharma plc (Nasdaq: VRNA) CEO Wins 'Executive of the Year 2023' at SCRIP Awards for Leadership in COPD Treatment. David Zaccardelli, Pharm. D., expressed gratitude to the Verona Pharma team for their efforts in bringing their first-in-class treatment to COPD patients worldwide. Ensifentrine is under review by the US FDA for COPD maintenance treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
none
-
Rhea-AI Summary
Verona Pharma plc (VRNA) announces senior management will present a company overview at upcoming healthcare conferences in November 2023. The conferences include Jefferies London Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and 6th Annual Evercore ISI HealthCONx Conference. Webcasts of each presentation will be available on the Company’s website. Contact information for investor and media inquiries is provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
none
Rhea-AI Summary
Verona Pharma announces FDA acceptance of NDA filing for ensifentrine for COPD maintenance treatment. PDUFA target action date set for June 26, 2024. Commercial launch preparations underway. Company presents positive Phase 3 trial results and launches disease awareness campaign.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
-
Rhea-AI Summary
Verona Pharma to report Q3 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences earnings
-
Rhea-AI Summary
Verona Pharma announces Investor Update in New York City
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences
Rhea-AI Summary
Verona Pharma announces positive results from Phase 3 ENHANCE studies with ensifentrine for COPD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences clinical trial
-
Rhea-AI Summary
Verona Pharma announces FDA acceptance of NDA for ensifentrine, with a target action date of June 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
Rhea-AI Summary
Verona Pharma announces positive results from Phase 3 ENHANCE-1 study with ensifentrine for COPD treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences clinical trial
Rhea-AI Summary
Verona Pharma appoints Christina Ackermann as Non-Executive Director
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
none

FAQ

What is the current stock price of Verona Pharma plc (VRNA)?

The current stock price of Verona Pharma plc (VRNA) is $37.86 as of November 21, 2024.

What is the market cap of Verona Pharma plc (VRNA)?

The market cap of Verona Pharma plc (VRNA) is approximately 3.2B.

What is Verona Pharma plc?

Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for respiratory diseases with significant unmet medical needs.

What is Ensifentrine?

Ensifentrine is Verona Pharma's lead therapeutic candidate, currently in development for treating chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).

What diseases does Verona Pharma target?

Verona Pharma targets respiratory diseases, including chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

Where is Verona Pharma listed?

Verona Pharma is listed on the NASDAQ Global Market under the ticker symbol VRNA and on the London Stock Exchange.

Who leads Verona Pharma?

Verona Pharma is led by a team with deep industry experience, including extensive backgrounds in the discovery, development, and commercialization of respiratory therapies.

What recent achievements has Verona Pharma made?

Recent achievements include the successful completion of Phase 2 clinical trials for Ensifentrine, showing promising results in improving lung function and reducing symptoms in COPD patients.

What are Verona Pharma’s near-term milestones?

The near-term milestones include advancing Ensifentrine into Phase 3 clinical trials and exploring potential marketing authorizations.

Does Verona Pharma have any partnerships?

Yes, Verona Pharma has established relationships with leading research institutions and advocacy organizations in the respiratory health sector.

What awards has Verona Pharma received?

Verona Pharma has received several awards in support of its innovative work in developing therapies for respiratory diseases.

How can I stay updated on Verona Pharma?

You can stay updated on Verona Pharma by following the latest news and press releases on their official website or stock market updates.

Verona Pharma plc

Nasdaq:VRNA

VRNA Rankings

VRNA Stock Data

3.18B
68.56M
4.11%
89.37%
9.19%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LONDON